Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells

Lee,Jaehyung; Gollahon,Lauren

doi:10.3892/ijo.2013.1788

Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells

Authors:
- Jaehyung Lee
- Lauren Gollahon
View Affiliations

Affiliations: Department of Biological Sciences, Texas Tech University, Lubbock, TX, USA
Published online on: January 22, 2013 https://doi.org/10.3892/ijo.2013.1788
Pages: 839-847
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the anticancer drugs paclitaxel and doxorubicin are commonly used to treat many solid tumors, their effectiveness is highly variable due to tumor cell resistance. Therefore, it is important to find mechanisms that can be targeted to increase the sensitivity of cancer cells to current chemotherapeutic agents. NIMA‑related kinase 2 (Nek2), a serine/threonine kinase is emerging as an important oncogene because of its regulatory role in mitosis. Thus, regulation of the Nek2 expression levels may prove important as a target for cancer treatment. The purpose of our study was to determine whether drug sensitivity was increased in the triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-468 by using small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) against Nek2. To this end, MDA-MB-231 and MDA-MB-468 breast cancer cells transfected with Nek2 siRNA or ASO were exposed to various concentrations of paclitaxel and doxorubicin. Cell viability, cell cycle distribution and apoptosis were evaluated. We observed that drug susceptibility in these transfected cells was dramatically increased compared with either agent alone. FACS results showed that apoptosis was induced in siRNA- and ASO‑transfected cells as expected due to the regulatory function of Nek2 in centrosome duplication. Interestingly, the cell cyle was not arrested in transfected cells. We found that siRNA and ASO against Nek2 worked synergistically with paclitaxel and doxorubicin by promoting cell apoptosis. Our results suggest that these drugs in combination with Nek2 siRNA or ASO treatment may improve the sensitivity of cancer cells during chemotherapy treatments.

View Figures

View References

1	Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825–2831. 1998.
2	Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
3	Rakha EA and Ellis IO: Triple-negative/basal-like breast cancer: review. Pathology. 41:40–47. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer - current status and future directions. Ann Oncol. 20:1913–1927. 2009. View Article : Google Scholar : PubMed/NCBI
5	Carey L, Winer E, Viale G, Cameron D and Gianni L: Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 7:683–692. 2010. View Article : Google Scholar : PubMed/NCBI
6	Pérez de Castro I, de Cárcer G, Montoya G and Malumbres M: Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol. 8:375–383. 2008.PubMed/NCBI
7	Chi YH and Jeang KT: Aneuploidy and cancer. J Cell Biochem. 102:531–538. 2007. View Article : Google Scholar
8	Kops GJ, Weaver BA and Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 5:773–785. 2005. View Article : Google Scholar : PubMed/NCBI
9	Yuen KW, Montpetit B and Hieter P: The kinetochore and cancer: what’s the connection? Curr Opin Cell Biol. 17:576–582. 2005.
10	Fry AM, Mayor T and Nigg EA: Regulating centrosomes by protein phosphorylation. Curr Top Dev Biol. 49:291–312. 2000. View Article : Google Scholar : PubMed/NCBI
11	Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32. 2001. View Article : Google Scholar : PubMed/NCBI
12	Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R and Miyakawa I: Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 169:41–49. 2001. View Article : Google Scholar : PubMed/NCBI
13	Holtrich U, Wolf G, Bräuninger A, et al: Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA. 91:1736–1740. 1994. View Article : Google Scholar : PubMed/NCBI
14	Li D, Zhu J, Firozi PF, et al: Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 9:991–997. 2003.PubMed/NCBI
15	Bettencourt-Dias M and Glover DM: Centrosome biogenesis and function: centrosomics brings new understanding. Nat Rev Mol Cell Biol. 8:451–463. 2007. View Article : Google Scholar : PubMed/NCBI
16	Krämer A, Neben K and Ho AD: Centrosome aberrations in hematological malignancies. Cell Biol Int. 29:375–383. 2005.
17	Nigg EA: Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer. 2:815–825. 2002. View Article : Google Scholar : PubMed/NCBI
18	Schultz SJ, Fry AM, Sütterlin C, Ried T and Nigg EA: Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans. Cell Growth Differ. 5:625–635. 1994.PubMed/NCBI
19	Fry AM, Schultz SJ, Bartek J and Nigg EA: Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of Aspergillus nidulans. J Biol Chem. 270:12899–12905. 1995. View Article : Google Scholar : PubMed/NCBI
20	Fry AM, Meraldi P and Nigg EA: A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J. 17:470–481. 1998. View Article : Google Scholar : PubMed/NCBI
21	Faragher AJ and Fry AM: Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell. 14:2876–2889. 2003. View Article : Google Scholar : PubMed/NCBI
22	Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM and Fry AM: The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 64:7370–7376. 2004. View Article : Google Scholar : PubMed/NCBI
23	Tsunoda N, Kokuryo T, Oda K, et al: Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci. 100:111–116. 2009. View Article : Google Scholar : PubMed/NCBI
24	Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y and Hamaguchi M: Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangio-carcinoma. Cancer Res. 67:9637–9642. 2007. View Article : Google Scholar : PubMed/NCBI
25	Crown J and Pegram M: Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat. 79(Suppl 1): S11–S18. 2003. View Article : Google Scholar : PubMed/NCBI
26	Wei R, Ngo B, Wu G and Lee WH: Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell. 22:3584–3594. 2011. View Article : Google Scholar : PubMed/NCBI
27	Jordan MA and Wilson L: Microtubules as a target for anti-cancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar
28	Blajeski AL, Kottke TJ and Kaufmann SH: A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res. 270:277–288. 2001. View Article : Google Scholar : PubMed/NCBI
29	Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ and Hickson ID: Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta. 1400:121–137. 1998. View Article : Google Scholar : PubMed/NCBI
30	Nitiss JL and Beck WT: Antitopoisomerase drug action and resistance. Eur J Cancer. 32A:958–966. 1996. View Article : Google Scholar : PubMed/NCBI
31	Spallarossa P, Altieri P, Aloi C, et al: Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol. 297:H2169–H2181. 2009. View Article : Google Scholar : PubMed/NCBI
32	Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A and Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 296:1000–1004. 2002. View Article : Google Scholar : PubMed/NCBI
33	Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M and Strebhardt K: Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst. 94:1863–1877. 2002.PubMed/NCBI
34	Tsui P, Rubenstein M and Guinan P: siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer. In Vivo. 19:653–656. 2005.PubMed/NCBI
35	Lou Y, Yao J, Zereshki A, et al: NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling. J Biol Chem. 279:20049–20057. 2004. View Article : Google Scholar : PubMed/NCBI
36	Fletcher L, Cerniglia GJ, Yen TJ and Muschel RJ: Live cell imaging reveals distinct roles in cell cycle regulation for Nek2A and Nek2B. Biochim Biophys Acta. 1744:89–92. 2005. View Article : Google Scholar : PubMed/NCBI
37	Prime G and Markie D: The telomere repeat binding protein Trf1 interacts with the spindle checkpoint protein Mad1 and Nek2 mitotic kinase. Cell Cycle. 4:121–124. 2005. View Article : Google Scholar : PubMed/NCBI